Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ozanimod - Celgene Corporation

Next Previous
Drug Profile

Ozanimod - Celgene Corporation

Alternative Names: BMS-986374; Ozanimod-HCl; Ozanimod-hydrochloride; RPC-1063; RPC-1063-HCl; ZEPOSIA

Latest Information Update: 29 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator The Scripps Research Institute
  • Developer Bristol-Myers Squibb; Celgene Corporation; Receptos
  • Class Amines; Anti-inflammatories; Benzene derivatives; Indenes; Nitriles; Oxadiazoles; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ulcerative colitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis; Ulcerative colitis
  • Phase III Crohn's disease

Most Recent Events

  • 30 Sep 2025 Celgene completes phase-II/III clinical trials in Ulcerative colitis in Japan (PO) (NCT03915769)
  • 24 Sep 2025 Updated efficacy data from the phase III ENLIGHTEN trial in Multiple sclerosis presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-2025)
  • 15 May 2025 Celgene terminates phase III trial in Multiple sclerosis (Treatment-experienced) in Canada, Puerto Rico, USA due to change business objective (PO) (NCT04140305)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top